Trial Profile
Randomized Phase II Study of Induction Bevacizumab, Etoposide and Cisplatin Followed by Whole Brain Radiotherapy (WBRT) Versus WBRT Alone in Breast Cancer With Untreated Brain Metastases
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 May 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin; Etoposide; Granulocyte colony-stimulating factors
- Indications Advanced breast cancer; Brain metastases
- Focus Therapeutic Use
- Acronyms A-PLUS
- 06 May 2021 Planned End Date changed from 1 Jul 2020 to 1 Nov 2022.
- 31 May 2020 Primary endpoint (The Brain-specific progression free survival (BS-PFS)) has been met.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology